

Express Mail No.: EL615431856US

DATE MAILED: July 26, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of:
Boyer, et al.

Appl. No. 10/814,007

Filed: March 30, 2004

For: COMPOSITIONS AND
METHOD FOR INHIBITING
PLATELET AGGREGATION

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Attorney Docket: 03678.0064.CPUS02

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22213-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
 - ☐ c. Attached is our Check No. _____ in the amount of _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the

Information Disclosure Statement be considered. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).

- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☒ 8. Copies of documents marked by * were cited by or submitted to the Office in Application Nos. 09/934,970, filed August 21, 2001; and 09/643,138 filed August 21, 2000;


which are relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 03678.0064.CPUS02.


Respectfully submitted,

Date: July 26, 2004



Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Ave.
Box No. 34
Menlo Park, CA 94025
Ph. (650) 463-8181
Fax (650) 463-8400

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p>PTO FORM 1449</p>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	1. *	5,049,550	09/17/91	Zamecnik	514	47	11/21/88	
	2. *	5,654,285	08/05/97	Ingall, et al.	514	47	06/06/95	
	3. *	5,681,823	10/28/97	Kim, et al.	514	47	05/02/96	
	4. *	5,721,219	02/24/98	Ingall, et al.	514	47	08/09/95	
	5. *	5,747,496	05/05/98	Cox, et al.	514	258	07/04/96	
	6. *	5,814,609	09/29/98	Markland, Jr. et al.	514	12	11-08-96	
	7. *	5,837,861	11/17/98	Pendergast, et al.	536	25.6	02/10/97	
	8. *	5,900,407	05/04/99	Yerxa, et al.	514	47	02/06/97	
	9. *	5,955,447	09/21/99	Ingall, et al.	514	47	08/28/97	
	10. *	6,166,022	12/26/00	Brown, et al.	514	258	07/15/98	
	11. *	6,323,187	11/27/01	Yerxa, et al.	514	51	05/21/99	
	12.	6,348,589	02/19/02	Pendergast, et al.	536	25.6	02/06/98	
	13.	6,596,725	07/22/03	Peterson, et al.	514	25.6	01/30/01	
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	14. *	WO 92/ 01673	07/11/91	PCT			X	
	15. *	WO 92/17488	10/15/92	PCT			X	
	16. *	WO 94/08593	28/04/94	PCT			X	
	17. *	WO 94/18216	08/18/94	PCT			X	
	18. *	WO 97/03084	01/30/97	PCT			X	
	19. *	WO 97/29456	21/08/97	PCT			X	
	20. *	WO 98/03182	29/01/98	PCT			X	
	21. *	WO 98/28300	07/02/99	PCT			X	
	22. *	WO 98/34593	13/08/98	PCT			X	
	23. *	WO 99/01138	14/01/99	PCT			X	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	03678.0064.CPUS02	10/814,007
	APPLICANT	
	Jose L. BOYER, et al.	
	FILING DATE	GROUP
	30 March 2004	

	24. *	WO 99/32085	01/07/99	PCT			X	
	25. *	WO 00/33080	06/08/00	PCT			X	
	26. *	WO 00/34283	06/15/00	PCT			X	
	27. *	WO 00/39145	06/07/00	PCT			X	
	28. *	WO 00/50024	31/08/00	PCT			X	
	29. *	WO 01/19826	03/22/01	PCT			X	
	30.	WO 01/39781	07/06/01	PCT			X	
	31. *	WO 01/36421	05/25/01	PCT			X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	32. *	Alessi, D. et al., "Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle" <i>Biochemistry</i> (1992), 31(34), 8043-54.						
	33. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients," <i>Br. Med. J.</i> 308: 81-106 (1994)						
	34. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy, " <i>Br. Med. J.</i> 308: 159-168 (1994)						
	35. *	Antman, E, for The TIMI 9a investigators, "Hirudin in Acute Myocardial Infarction," <i>Circulation</i> , 90(4):1624-1630 (1994)						
	36. *	Bernat, A., et al., "Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat," <i>Thromb. Haemostas.</i> (1993) 70(5):812-816						
	37. *	Bujalowski, W. et al., "Structural Characteristics of the Nucleotide-Binding Site of <i>Escherichia coli</i> Primary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs" <i>Biochemistry</i> (1994), 33(15), 4682-94.						
	38. *	Bush, L., et al., "Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries," <i>Circulation</i> 69(6):1161-1170, (1984)						
	39. *	Cardullo, R. A. et al., "Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase" <i>Analytical Biochemistry</i> (1990), 188(2), 305-9.						
	40. *	Carvalho-Alves, P. et al., "Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase" <i>Journal of Biological Chemistry</i> (1985), 260(7), 4282-7.						
	41. *	Chapal, J. et al., "Comparative effects of adenosine-5'-triphosphate and related analogs on insulin secretion from the rat pancreas" <i>Fundamental & Clinical Pharmacology</i> (1997), 11(6), 537-545.						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p align="center">PTO FORM 1449</p>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

42. *	Folts, J. et al., "Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian," <i>Circulation</i> 54 (3):365-370 (1976)
43. *	Frederick, L.G., et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canine Model of Coronary Artery Thrombosis," <i>Circulation</i> 93 (1):129-134 (1996)
44. *	Geiger, J., et al., "Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19 :2007-2011 (1999)
45. *	Hass, W., et al., "A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients," <i>N. Engl. J. Med.</i> , 321 (8):501-507 (1989)
46. *	Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits," <i>Arterioscl. Thromb.</i> (1993) 13 (8):1171-1179
47. *	Hiratsuka, Toshiaki, "Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2',3'-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives" <i>Biochimica et Biophysica Acta</i> (1982), 719 (3), 509-17.
48. *	Hiratsuka, Toshiaki, "Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP" <i>Biophysical Journal</i> (1997), 72 (2, Pt. 1), 843-849.
49. *	Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, March 29-31, 2000
50. *	Humphries, R.G., et al., "Pharmacological profile of the novel P2T-Purinoreceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vitro," <i>Br. J. Pharmacol.</i> 115 :1110-1116 (1995)
51. *	Ikehara, M. et al., "III. Interaction Between Synthetic Adenosine Triphosphate Analogs and Actomyosin Systems" <i>Biochimica et Biophysica Acta</i> (1965), 100 (2), 471-8.
52. *	Ikehara, M. et al., "Unusual Rapid Cleavage of Terminal Phosphate Group of N6-Disubstituted Adenosine 5'-Triphosphate (ATP) by Divalent Cation" <i>Biochimica et Biophysica Acta</i> (1964), 85 (3), 512-515.
53. *	Ingall, A., et al., "Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy," <i>J. Med. Chem.</i> 42 : 213-220 (1999)
54. *	Kim, et al., "Characterization of the Purinergic P ₂ Receptors in PC12 Cells," <i>Journal of Biological Chemistry</i> (1994), 269 :6471-6477.
55. *	Kwiatkowski, A. et al., "Mapping of the Adenosine 5'-Triphosphate Binding Site of Type II Calmodulin-Dependent Protein Kinase" <i>Biochemistry</i> (1987), 26 (24), 7636-40.
56. *	Lazarowski, E., et al., "Pharmacological selectivity of the cloned human P2u-purinoreceptor: potent activation by diadenosine tetraphosphate," <i>Brit. J. Pharm.</i> 116 :1619-1627 (1995)
57. *	Lekstrom, J and William R. Bell, "Asprian in the Prevention of Thrombosis," <i>Medicine</i> 70 (3):161-178 (1991)
58. *	Lowe, G. et al., "Evidence of a Dissociative S _N 1(P) Mechanism of Phosphoryl Transfer by Rabbit

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p align="center">PTO FORM 1449</p>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

		Muscle Pyruvate Kinase" <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> (1972-1999) (1978), (12), 1622-30.
59.	*	Marian, M., "Acetyl Derivatives of Nucleoside 5'-Triphosphates. I." <i>Microchemical Journal</i> (1984), 29(2), 219-27.
60.	*	Mayer, I. et al., "Interaction of Fluorescent Adenine Nucleotide Derivatives with the ADP/ATP Carrier in Mitochondria. 1. Comparison of Various 3'-O-Ester Adenine Nucleotide Derivatives" <i>Biochemistry</i> (1984), 23(11), 2436-42.
61.	*	Mickelson, J.K., et al., "Antiplatelet Antibody [7E3 F(ab') ₂] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a Canine Model," <i>Circulation</i> 81(2):617-627 (1990)
62.	*	Murataliev, M. et al., "Interaction of mitochondrial F ₁ -ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate" <i>European Journal of Biochemistry</i> (1995), 232(2), 578-85.
63.	*	Neuhaus., K. L. et al., "Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study," <i>Circulation</i> , 90(4): 1638-1642 (1994)
64.	*	Oliveira, C. R. G. et al., "Interaction of Spin-Labeled Nucleotides with Sarcoplasmic Reticulum Adenosinetriphosphatase" <i>Biochemistry</i> (1988), 27(16), 5923-7.
65.	*	Olivier, K., et al., "Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5' - Triphosphate + Amiloride in Normal Human Adults," - <i>Am. J. Respir. Crit. Care Med.</i> 154:217-223 (1996)
66.	*	Quinn, M and Desmond J. Fitzgerald, "Ticlopidine and Clopidogrel," <i>Circulation</i> 100(15):1667-1672 (1999)
67.	*	Ray, S. et al., "Microenvironment at the Substrate Binding Subsite of the Active Site of UDPglucose 4-Epimerase from <i>Kluyveromyces Fragilis</i> Using a Fluorescent Analog of UMP" <i>Indian Journal of Biochemistry & Biophysics</i> (1992), 29(2), 209-13.
68.	*	Romson, J., et al., "Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Thrombotic Agents," <i>Thromb. Res.</i> 17:841-853 (1980)
69.	*	Seebregts, C. et al., "2',3'-O-(2,4,6-Trinitrophenyl)-8-Azido-adenosine Mono-, Di-, and Triphosphates as Photoaffinity Probes of the Ca ²⁺ -ATPase of Sarcoplasmic Reticulum. Regulatory/Superfluorescent Nucleotides Label the Catalytic Site with High Efficiency" <i>Journal of Biological Chemistry</i> (1989), 264(4), 2043-52.
70.	*	Shebuski, R., et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusion by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canine Model of Coronary Thrombosis," <i>Circulation</i> 82(1):169-177 (1990)
71.	*	Soslau, G. et al., "Aggregation of Human and Canine Platelets: Modulation by Purine Nucleotides" <i>Thrombosis Research</i> (1993), 72(2), 127-37.
72.	*	Thoenges D. et al., "Tight Binding of Bulky Fluorescent Derivatives of Adenosine to the Low Affinity E ₂ ATP Site Leads to Inhibition of Na ⁺ /K ⁺ -ATPase. Analysis of Structural Requirements of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i></p> <p align="center">PTO FORM 1449</p>	<p>ATTY. DOCKET NO.</p> <p>03678.0064.CPUS02</p>	<p>APPLICATION NO.</p> <p>10/814,007</p>
	<p>APPLICANT</p> <p>Jose L. BOYER, et al.</p>	
	<p>FILING DATE</p> <p>30 March 2004</p>	<p>GROUP</p>

		Fluorescent ATP Derivatives with a Koshland-Nemethy-Filmer Model of Two Interacting ATP Sites" <i>Journal of Biological Chemistry</i> (1999 Jan 22), 274(4), 1971-8.
	73. *	Tschopp, J.F., et al., " Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time," <i>Coron. Artery Dis.</i> 4:809-817(1993)
	74. *	Vigne, P. et al., "Benzoyl ATP Is an Antagonist of Rat and Human P2Y ₁ Receptors and of Platelet Aggregation" <i>Biochemical and Biophysical Research Communications</i> (1999), 256(1), 94-97.
	75. *	Ward, D. et al., "Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2'(3')-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5'-Diphosphate. Abolition of E1 and E2 Partial Reactions by Sequential Block of High and Low Affinity Nucleotide Sites" <i>Journal of Biological Chemistry</i> (1998), 273(23), 14277-14284.
	76. *	Weber, M., et al., "Low-Dose Aspirin Verses Anticoagulants for Prevention of Coronary Graft Occlusion," <i>Am. J. Cardiol.</i> 66:1461-1468 (1990)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.